It activates three different metabolic receptors, and two of those, the glucagon receptor and the GIP receptor, do things that go beyond making you eat less
But patients are at the heart of the GLP-1 trend, and the Obesity Action Coalition is there to provide support, education and advocacy for those who want to use these medications as part of their weight-loss plan
2Get results Results include insights from top doctors, a detailed clinicians summary, and an immediate call for critical results
Location: Plainsboro, New JerseyWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Wegovy (semaglutide) injection, for subcutaneous use, Ozempic (semaglutide) injection, for subcutaneous use, and Victoza (liraglutide) injection, for subcutaneous use.FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Novo Nordisk promoted Wegovy, Ozempic, and Victoza in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner
